Cargando…

Unexpected Adverse Events of Immune Checkpoint Inhibitors

The introduction of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment standards and significantly enhanced patient prognoses. However, the utilization of these groundbreaking therapies has led to the observation and reporting of various types of adverse events, commonly known a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shalata, Walid, Yakobson, Alexander, Cohen, Aharon Y., Goldstein, Iris, Saleh, Omar Abu, Dudnik, Yulia, Rouvinov, Keren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455121/ https://www.ncbi.nlm.nih.gov/pubmed/37629514 http://dx.doi.org/10.3390/life13081657

Ejemplares similares

Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors
por: Yakobson, Alexander, et al.
Publicado: (2023)

A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2022)

Radiotherapy-Induced Atrial Myxoma: A Case Report and Literature Review
por: Shalata, Walid, et al.
Publicado: (2023)

Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
por: Rouvinov, Keren, et al.
Publicado: (2023)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
por: Shalata, Walid, et al.
Publicado: (2023)

Unexpected and Rare Sites of Metastasis in Oncologic Patients
por: Shalata, Walid, et al.
Publicado: (2023)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
por: Shalata, Walid, et al.
Publicado: (2021)

Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
por: Shalata, Walid, et al.
Publicado: (2023)

PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
por: Yakobson, Alexander, et al.
Publicado: (2023)

Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
por: Shalata, Walid, et al.
Publicado: (2023)

Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer
por: Kian, Waleed, et al.
Publicado: (2020)

Metabolic Activity Assessment by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients after COVID-19 Vaccination
por: Shalata, Walid, et al.
Publicado: (2022)

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?
por: Shalata, Walid, et al.
Publicado: (2021)

Associated Myocarditis: A Predictive Factor for Response?
por: Shalata, Walid, et al.
Publicado: (2020)

Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
por: Yakobson, Alexander, et al.
Publicado: (2023)

Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience
por: Shalata, Walid, et al.
Publicado: (2022)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
por: Rouvinov, Keren, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review
por: Shalata, Walid, et al.
Publicado: (2023)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
por: Poto, Remo, et al.
Publicado: (2022)

Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors
por: Rogers, Barbara Barnes, et al.
Publicado: (2021)

Thyroid-related adverse events induced by immune checkpoint inhibitors
por: Chera, Alexandra, et al.
Publicado: (2022)

Pancreatic adverse events in patients treated with immune checkpoint inhibitors
por: Hana, Caroline, et al.
Publicado: (2023)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Litigations for Unexpected Adverse Events
por: Fong, I. W.
Publicado: (2010)

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future
por: Szeto, Chun Ho, et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
por: Nakamura, Yoshiyuki
Publicado: (2019)

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
por: Li, Li, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m4omlo150iif7698ej04dvcihj